Kangfang TIGIT/TGF-β dual-target antibody fusion protein preclinical research results were released for the first time at the European Society for Oncology (ESMO) annual meeting, the European Society for Oncology (ESMO) announced the preclinical research results of its world-first TIGIT/TGF-β dual-target antibody fusion protein AK130, at the annual meeting of the authoritative society in the field of tumors. Studies have shown that AK130 can specifically bind TIGIT and TGF-β and has high affinity; it displays a strong anti-tumor effect, and does not have the effects of ADCC and CDC, and is safer. The results of preclinical research fully support its clinical development in the direction of anti-tumor treatment.
More hot information, insight analysis, research reports, live lectures... Please pay attention to [Hard Technology]
Welcome to search for [Hard Technology] on major platforms and identify the account of the blue logo!
Advanced financial services for millions of "hard technology" enterprises in China to create a better future together! We focus on industries such as optoelectronic chips, artificial intelligence , aerospace, new energy, smart cars, biomedicine , science and technology finance, and rely on the unique technological intelligence data advantages of Smart Ya , scientific and technological innovation intelligence and information SaaS service provider Smart Ya , and see technical trends with readers, understand the hard technology industry, and connect to the future of innovation. "Hard Technology" is produced by the Smart Yao Innovation Research Center.
